ConductScience.org, home

Paper32276005

Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy.

Kim B and 6 others. J Control Release, 2020. Cited by 56 papers, by iCite.

Cite this record

ConductScience Library. Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy. Papers, record 32276005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32276005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy.
PubMed
Journal
J Control Release
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
56
iCite
Relative citation ratio, by iCite
3
iCite
Revised in PubMed
2021-06-17
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kim BBaksun
2Shin JJaeho
3Wu JJunmin
4Omstead DTDavid T
5Kiziltepe TTanyel
6Littlepage LELaurie E
7Bilgicer BBasar

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
NanoparticlesMajor topic
Animals
Cell Line, Tumor
Doxorubicin
Drug Delivery Systems
Female
Humans
Mice
Peptides
Reproducibility of Results

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R33 CA206922NCI NIH HHSUnited StatesR33CA206922PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127196779Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma.Mol Cancer Ther2016https://conductscience.org/library/papers/27196779PubMed
223116010Multivalent ligand: design principle for targeted therapeutic delivery approach.Ther Deliv2012https://conductscience.org/library/papers/23116010PubMed
324003770Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length.ACS Nano2013https://conductscience.org/library/papers/24003770PubMed
418481173PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.Breast Cancer Res Treat2009https://conductscience.org/library/papers/18481173PubMed
531473250Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro.J Control Release2019https://conductscience.org/library/papers/31473250PubMed
618937508Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.Bioconjug Chem2008https://conductscience.org/library/papers/18937508PubMed
723841107Functionalized liposome purification via Liposome Extruder Purification (LEP).Analyst2013https://conductscience.org/library/papers/23841107PubMed
823330947Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.Br J Pharmacol2013https://conductscience.org/library/papers/23330947PubMed
930361524Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.Br J Cancer2018https://conductscience.org/library/papers/30361524PubMed
1017611206Trastuzumab--mechanism of action and use in clinical practice.N Engl J Med2007https://conductscience.org/library/papers/17611206PubMed
1118272481Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.Proc Natl Acad Sci U S A2008https://conductscience.org/library/papers/18272481PubMed
1226149286The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment.ACS Nano2015https://conductscience.org/library/papers/26149286PubMed
1310606988Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice.Clin Exp Immunol2000https://conductscience.org/library/papers/10606988PubMed
1423776619Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging.PLoS One2013https://conductscience.org/library/papers/23776619PubMed
1529751334Treatment of advanced HER2-positive breast cancer: 2018 and beyond.Cancer Treat Rev2018https://conductscience.org/library/papers/29751334PubMed
1617579068Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.J Immunol2007https://conductscience.org/library/papers/17579068PubMed
1726295142Improved Peptide-Targeted Liposome Design Through Optimized Peptide Hydrophilicity, Ethylene Glycol Linker Length, and Peptide Density.J Biomed Nanotechnol2015https://conductscience.org/library/papers/26295142PubMed
1812360278Ligand-targeted therapeutics in anticancer therapy.Nat Rev Cancer2002https://conductscience.org/library/papers/12360278PubMed
191359541Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.Proc Natl Acad Sci U S A1992https://conductscience.org/library/papers/1359541PubMed
2021406401Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.Cancer Res2011https://conductscience.org/library/papers/21406401PubMed

See all 43 referencesDownload CSV of references

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.

PMIDTitleJournalYearIn PapersSource
42974396Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles.Nanoscale Adv2026https://conductscience.org/library/papers/42974396PubMed
4235309617-DMAG-Loaded HER2-Targeted Extracellular Vesicles Induce PARP/Caspase3-Mediated Apoptosis in Gastric Carcinoma.Int J Mol Sci2026https://conductscience.org/library/papers/42353096PubMed
41660126Advancing precision tumor therapy: Progress in targeted delivery of peptide-based nanomaterials from microenvironment to organelles.Mater Today Bio2026https://conductscience.org/library/papers/41660126PubMed
40838213Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery.Mater Today Bio2025https://conductscience.org/library/papers/40838213PubMed
40747717Role of miRNA‑214‑3p in cancer (Review).Oncol Rep2025https://conductscience.org/library/papers/40747717PubMed
40584785Developing the Strategy to Use Silk Spheres for Efficient, Targeted Delivery of Oligonucleotide Therapeutics to Cancer Cells.Int J Nanomedicine2025https://conductscience.org/library/papers/40584785PubMed
40176316Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.ACS Nano2025https://conductscience.org/library/papers/40176316PubMed
40094065Advances in nanotechnology for targeting cancer-associated fibroblasts: A review of multi-strategy drug delivery and preclinical insights.APL Bioeng2025https://conductscience.org/library/papers/40094065PubMed
39271060Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer.J Control Release2024https://conductscience.org/library/papers/39271060PubMed
39100472Albumin incorporation into recognising layer of HER2-specific magnetic nanoparticles as a tool for optimal targeting of the acidic tumor microenvironment.Heliyon2024https://conductscience.org/library/papers/39100472PubMed
39050885Recent advanced lipid-based nanomedicines for overcoming cancer resistance.Cancer Drug Resist2024https://conductscience.org/library/papers/39050885PubMed
38961887Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting.Nanotheranostics2024https://conductscience.org/library/papers/38961887PubMed
38660023EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.Int J Nanomedicine2024https://conductscience.org/library/papers/38660023PubMed
38126905Nanotechnology Applications in Breast Cancer Immunotherapy.Small2024https://conductscience.org/library/papers/38126905PubMed
37686984Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics.Nanomaterials (Basel)2023https://conductscience.org/library/papers/37686984PubMed
37633875Synthesis Folate-linked Chitosan-coated Quetiapine/BSA Nano-Carriers as the Efficient Targeted Anti-Cancer Drug Delivery System.Mol Biotechnol2024https://conductscience.org/library/papers/37633875PubMed
36794282Recent advances in peptide-based therapeutic strategies for breast cancer treatment.Front Pharmacol2023https://conductscience.org/library/papers/36794282PubMed
36632508Functionalized liposomes for targeted breast cancer drug delivery.Bioact Mater2023https://conductscience.org/library/papers/36632508PubMed
36499301The Impact of Nanobody Density on the Targeting Efficiency of PEGylated Liposomes.Int J Mol Sci2022https://conductscience.org/library/papers/36499301PubMed
36374573Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis.Mol Pharm2023https://conductscience.org/library/papers/36374573PubMed

See all 34 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32276005

GET https://conductscience.org/api/papers/v1/32276005/references?page=2